Import from '@/components'

Nurtec ODT (Rimegepant) Cardiovascular Impact Long-Term: A Women's Guide

Why Cardiovascular Safety Matters Specifically for Women With Migraine

Migraine is not just a headache disorder. Women are three times more likely than men to have migraine, and migraine with aura in women under 45 is independently associated with a roughly doubled risk of ischemic stroke. That stroke connection is why the cardiovascular profile of every migraine drug prescribed to women deserves careful attention.

Triptans, for decades the first-line acute treatment, are serotonin 5-HT1B/1D agonists. They work partly through vasoconstriction. Coronary and cerebral arterial constriction is their mechanism of action and their liability. That is why triptans carry a contraindication in women with uncontrolled hypertension, coronary artery disease, prior stroke, or hemiplegic migraine.

Rimegepant works differently. It is a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist. CGRP is a potent vasodilator neuropeptide released from trigeminal afferents during a migraine attack. Rimegepant blocks the receptor rather than causing contraction of the vessel wall. This distinction is pharmacologically significant for women who have been told they cannot take triptans.

The Triptan-Cardiovascular Problem Women Know Too Well

Many women with migraine and aura, or migraine combined with hypertension, oral contraceptive use, or a history of smoking, have been turned away from triptans. The standard clinical logic holds: add vasoconstrictive drugs on top of an already-elevated vascular risk, and you may tip someone toward an event.

ACOG's guidance on migraine management in women notes that combined hormonal contraceptives are relatively contraindicated in women with migraine with aura precisely because of stroke risk, a consideration that overlaps directly with triptan decision-making.

Rimegepant entered this gap. Because it does not constrict blood vessels, the theoretical cardiovascular contraindications that apply to triptans were not expected to apply to gepants.

How CGRP Physiology Differs in Women

CGRP is not a neutral molecule from a hormonal standpoint. Estrogen upregulates CGRP expression in trigeminal neurons. This is one mechanistic reason why migraine prevalence peaks during the reproductive years and surges in perimenopause, when estrogen fluctuates unpredictably rather than cycling smoothly. CGRP levels measurably rise at the time of menstruation when estrogen drops, which is the biological basis of menstrual migraine.

Blocking the CGRP receptor therefore has a degree of hormonal relevance that extends beyond simple pain modulation. Women with menstrual migraine, defined as attacks occurring exclusively or predominantly within two days before through three days after the onset of menstruation, may respond to rimegepant through this estrogen-CGRP axis.

The Cardiovascular Mechanism of Rimegepant: What Is Actually Known

Rimegepant is a gepant. Gepants block the CGRP receptor competitively and reversibly. Because CGRP is a vasodilator, blocking it might theoretically reduce vasodilation. The concern in early gepant development was whether blocking a vasodilatory peptide could increase coronary tone or raise blood pressure over time.

What the Phase 2 and Phase 3 Data Show

In the key acute-treatment trials (BHV3000-301 and BHV3000-302), rimegepant 75 mg orally disintegrating tablet was compared with placebo. The pooled safety population across the acute trials exceeded 1,800 participants, and no increase in major adverse cardiovascular events (MACE) was observed in the rimegepant arm. Blood pressure changes were not statistically different from placebo.

These trials were relatively short, measured over a single treated attack per enrolled participant in the key design, so they do not answer the long-term question.

The prevention trial published in The Lancet in 2021 is the most relevant long-term dataset currently available. Rimegepant 75 mg every other day reduced mean monthly migraine days by 4.3 days versus 3.5 days for placebo over a 12-week treatment period, with a safety profile comparable to placebo and no clinically meaningful cardiovascular signals. Adverse cardiovascular events were reported at rates no higher than placebo across this 12-week maintenance period.

Open-Label Extension Safety: The 52-Week Picture

After the controlled trials, an open-label extension enrolled participants for up to approximately 52 weeks of continuous or near-continuous rimegepant use. The published extension data did not identify new cardiovascular safety signals. Blood pressure trajectories, heart rate, and electrocardiographic parameters did not shift in clinically significant ways. In the long-term safety cohort reported in the open-label extension, serious adverse events occurred in approximately 3% of participants, none of which were adjudicated as cardiovascular events causally related to rimegepant.

The honest caveat: 52 weeks is not ten years. Atherosclerosis, coronary artery disease progression, and stroke risk accumulate over decades. No randomized trial has followed gepant users for five or more years with cardiovascular endpoints as a primary outcome.

No Coronary Vasospasm Signal: The Ex Vivo Evidence

An important mechanistic data point comes from ex vivo studies on human coronary artery preparations. Unlike sumatriptan, which causes measurable constriction in isolated human coronary arteries, rimegepant did not cause significant coronary artery contraction in these preparations. This finding underpins the rationale for using gepants in patients with cardiovascular risk factors who cannot take triptans. The drug's pharmacology does not rely on vasoconstriction.

Long-Term Cardiovascular Safety: What Remains Unknown

Honesty about evidence gaps is a WomanRx commitment. Here is what is genuinely uncertain.

The CGRP-Cardiac Protection Question

CGRP has cardioprotective properties. It is released during ischemic preconditioning and may limit infarct size in animal models. Long-term pharmacological blockade of the CGRP receptor could theoretically attenuate this protective mechanism. No human trial has been powered to detect whether years of CGRP receptor blockade increases myocardial infarction risk. The monoclonal antibody CGRP pathway drugs (erenumab, fremanezumab, galcanezumab) have raised related questions; a 2021 BMJ pharmacovigilance analysis of CGRP-pathway preventive drugs found a small but detectable signal for hypertension, particularly with erenumab, which targets the receptor rather than the ligand. Rimegepant also targets the receptor, so this signal warrants watching, though rimegepant's shorter half-life (approximately 11 hours) and competitive reversible binding distinguish it mechanistically from the monoclonal antibodies.

Women With Hypertension: An Under-Studied Subgroup

The key trials did not prespecify sex-stratified or hypertension-stratified cardiovascular analyses, which is a notable evidence gap for a drug prescribed predominantly to women. Women develop hypertension at older average ages than men but experience faster progression in perimenopause and post-menopause. A woman starting rimegepant at 38 for menstrual migraine may still be using it at 53, when her cardiovascular risk profile is substantially different. No prospective data address this transition.

The Perimenopausal Cardiovascular-Migraine Intersection

Perimenopause is when migraine often worsens and cardiovascular risk begins to rise simultaneously. Vasomotor symptoms (hot flashes, night sweats) are themselves linked to adverse cardiovascular outcomes. The Study of Women's Health Across the Nation (SWAN) found that women with frequent vasomotor symptoms had higher markers of subclinical cardiovascular disease. Women managing both perimenopausal migraine and nascent cardiovascular risk represent exactly the population who may prefer rimegepant over triptans, yet they are the group with the least specific long-term gepant safety data.

Rimegepant in the Context of Female-Relevant Conditions

Migraine With Aura and Stroke Risk

Women with migraine with aura face the most complex risk calculus. Rimegepant is not contraindicated in migraine with aura (unlike combined hormonal contraceptives and, in some guidelines, high-dose estrogen-containing products). Because rimegepant does not cause vasoconstriction, it does not add the vasoconstrictive component that makes some clinicians uncomfortable using triptans in this population. A 2024 American Headache Society position paper supports gepants as first-line options in patients with cardiovascular risk factors or contraindications to triptans.

PCOS and Metabolic Cardiovascular Risk

Women with polycystic ovary syndrome (PCOS) have a higher prevalence of hypertension, insulin resistance, and dyslipidemia. No dedicated rimegepant data exist in a PCOS population. From a pharmacokinetic standpoint, rimegepant is primarily metabolized by CYP3A4. Drugs commonly used in PCOS, including metformin (not a CYP3A4 interactor) and combined oral contraceptives (moderate CYP3A4 inducers), may modestly affect rimegepant exposure, though this has not been studied in PCOS-specific trials.

Menstrual Migraine: The Life-Stage-Specific Use Case

Menstrual migraine affects roughly 7 to 14 percent of women who have migraine, and these attacks tend to be longer, more severe, and less responsive to acute treatment than non-menstrual attacks. Because CGRP rises around menses, rimegepant's mechanism is a direct match for this phenotype. The prevention trial's every-other-day dosing schedule is particularly suited to short-cycle prevention: a woman could use rimegepant every other day for the five to seven days surrounding menses rather than as a continuous daily preventive. This targeted strategy has not been studied in a dedicated menstrual migraine trial, but the Lancet 2021 prevention data provide the supportive framework.

Endometriosis and Chronic Pain Overlap

Women with endometriosis have higher rates of central sensitization and comorbid migraine. No specific rimegepant data exist in endometriosis cohorts. The cardiovascular implications are indirect: endometriosis is increasingly recognized as a marker for elevated cardiovascular risk later in life. A clinician prescribing rimegepant to a woman with endometriosis and migraine should document baseline blood pressure and revisit cardiovascular risk at each annual visit.

Pregnancy, Lactation, and Contraception Requirements

Rimegepant is contraindicated during pregnancy. This must be stated clearly and early: do not use rimegepant if you are pregnant or planning to become pregnant without discussing an alternative plan with your prescriber.

Pregnancy Safety Data

Human pregnancy data for rimegepant are essentially absent. Animal reproductive toxicology studies conducted with rimegepant showed developmental toxicity at doses higher than the maximum recommended human dose. Because CGRP plays a role in uterine vascular adaptation during pregnancy, there is a biological rationale for caution beyond the absence of human safety data. The FDA label for rimegepant notes that animal studies showed increased embryo-fetal mortality and skeletal variations at exposures above the human therapeutic level.

No established pregnancy category exists under the current FDA labeling system (the old A/B/C/D/X system was retired in 2015), but the label's risk-benefit language is essentially equivalent to a warning against use in pregnancy.

Lactation

Rimegepant is present in rat milk. Human lactation data are not available. The FDA label advises that the benefits and risks should be discussed with your provider. Given the absence of human data and the fact that acute migraine can often be managed with acetaminophen or non-pharmacological methods during lactation, most lactation specialists would prefer a cautious approach. If rimegepant is used while breastfeeding, expressing and discarding milk for at least 24 hours after each dose (approximately two half-lives) is one strategy, though this is not formally validated.

Contraception Requirements

Rimegepant is not classified as a teratogen requiring mandatory contraception in the same regulatory framework as valproate or isotretinoin. However, because pregnancy data are absent and animal data are concerning, any woman of reproductive potential who uses rimegepant for prevention (every-other-day dosing) should use reliable contraception. This is especially relevant because women using rimegepant to prevent menstrual migraine may inadvertently be taking it near the time of ovulation or early implantation if cycles are irregular. Discuss contraception explicitly with your prescriber before starting the preventive regimen.

If you become pregnant while taking rimegepant, stop the medication and contact your OB-GYN or midwife promptly. Enrollment in the rimegepant pregnancy registry (contact information available through the prescribing information) allows real-world safety data to be collected.

Who This Is Right For, and Who Should Pause

Women Who May Benefit Most

You may be a strong candidate for rimegepant if you:

• Have migraine with aura and cannot use estrogen-containing contraceptives or have been told triptans carry too much cardiovascular risk for you
• Have a history of hypertension, coronary artery disease, or prior TIA that makes your clinician uncomfortable prescribing a triptan
• Experience menstrual migraine that is poorly controlled with NSAIDs alone
• Are in perimenopause and find your migraine frequency has increased with hormonal fluctuation
• Have had medication-overuse headache with triptans and need an acute option with lower habituation risk (gepants appear not to cause rebound headache at standard frequencies)

Women Who Should Discuss Carefully or Avoid

• Currently pregnant or trying to conceive: rimegepant is not appropriate; discuss alternatives such as acetaminophen, magnesium, and non-pharmacological options
• Breastfeeding: discuss risks and alternatives; if used, consider the expressed-milk approach noted above
• Severe hepatic impairment: rimegepant exposure increases substantially; the label advises against use in severe hepatic impairment
• Concomitant use of strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) or strong CYP3A4 inducers (e.g., rifampin): these significantly alter rimegepant plasma levels
• Women taking P-glycoprotein inhibitors: rimegepant is a P-gp substrate; cyclosporine and certain other immunosuppressants can raise rimegepant exposure to potentially concerning levels

Life-Stage Summary Table

| Life Stage | Rimegepant Appropriateness | Key Consideration | |---|---|---| | Reproductive years, not TTC | Generally appropriate | Reliable contraception if using preventive dosing | | Trying to conceive | Not recommended | Discontinue before stopping contraception | | Pregnancy | Contraindicated | Switch to OB-approved acute options | | Postpartum and lactating | Use with caution | Absent human lactation data; discuss with provider | | Perimenopause | Appropriate; may be especially useful | Monitor BP annually as cardiovascular risk rises | | Post-menopause | Appropriate; assess cardiovascular risk baseline | No estrogen-CGRP interaction data post-menopause |

Dosing and Practical Use for Women

Rimegepant comes as a 75 mg orally disintegrating tablet (ODT). The tablet dissolves on the tongue without water. This formulation is practical during a migraine attack when nausea makes swallowing pills difficult, a symptom women report more frequently than men.

For acute treatment: 75 mg as a single dose; do not exceed one dose in 24 hours.

For prevention: 75 mg every other day. The Lancet 2021 trial used this exact schedule over 12 weeks and showed a statistically significant reduction in mean monthly migraine days compared with placebo (least-squares mean difference approximately 1.0 day; 95% CI 0.5 to 1.5).

A unique feature of rimegepant is that one drug covers both acute and preventive indications. A woman who takes it every other day for prevention can use an additional dose on a migraine day that falls on an off day, provided she does not exceed one dose in any 24-hour window.

Onset of action in acute treatment: pain freedom at two hours was achieved by 19.6% of rimegepant-treated patients versus 12.0% placebo in the BHV3000-301 trial. Sustained pain freedom (two to 48 hours) was statistically superior to placebo. These numbers are lower than some triptans in non-restricted populations, which is worth discussing honestly with your prescriber.

Monitoring and Follow-Up for Long-Term Cardiovascular Safety

Given the evidence gaps described above, the following monitoring framework is reasonable for women using rimegepant long-term:

• Baseline: blood pressure, heart rate, and a documented cardiovascular risk assessment using a tool such as the ACC/AHA 10-year ASCVD risk calculator for women over 40
• At 3 months: confirm blood pressure has not changed from baseline, review migraine days to assess preventive response
• Annually: repeat cardiovascular risk assessment; document any new cardiovascular diagnoses; revisit the risk-benefit discussion for continued use
• If new cardiovascular event occurs: pause rimegepant and consult cardiology before resuming

No guideline currently mandates specific cardiovascular monitoring for gepants. This framework reflects current clinical common sense given the CGRP pathway's vascular role and the open questions in long-term data. The 2023 American Headache Society consensus on CGRP-pathway drugs recommends annual reassessment but does not specify laboratory or imaging monitoring.